Aridis uses human antibodies to fight against “time bomb” of antibiotic resistance

Although antibodies have gained plenty of ground in recent years as vehicles for cancer therapies, Aridis Pharmaceuticals wants to use them as nature intended – to fight infection. “These are human monoclonal antibodies being investigated as anti-infectives to treat bacterial infections associated with pneumonia,” founder &CEO Vu Truong told Drug Delivery Business News, referring to the company’s projects that are in pivotal trials. “The fundamental reason is that this is exactly what the antibody is designed to do – that is, to fight infection,” he explained. Get the full story at our sister site, Drug Delivery Business News. The post Aridis uses human antibodies to fight against “time bomb” of antibiotic resistance appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Hospital Care Pharmaceuticals Research & Development aridispharmaceuticals Source Type: news

Related Links:

Conclusions In the span of a very short time—less than a decade—robotic head and neck surgery has transformed the management of the head and neck cancer, and it seems clear that the future of treatment for these cancers lies in a multimodal approach in which TORS is likely to play an important role. Nevertheless, it is important to keep in mind that the current indications for TORS are limited and long-term data on the safety and oncological outcomes are needed to better understand the true role of TORS in treatment of head and neck cancer. Nonetheless, the emergence of ever more advanced robotic instruments i...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Shen M, Cai L, Jiang K, Xu W, Chen Y, Xu Z Abstract Lung cancer represents a major healthy concern due to high incidence and morality. Increasing evidences showed critical regulatory role of microRNA (miR) in cell growth, differentiation and apoptosis. It has been indicated that the level of miR-328 is abnormally up regulated in lung cancer cell line, which is correlated with cell apoptosis. An in vitro lung cancer model was established through induction of chlamydia pneumonia. Western blot and real-time quantitative PCR were used to measure miR-328 level and its effects on histone H2AX expression. Bioinfo...
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Conclusions: At the 5-year follow-up of this phase III trial, there was a numerical but statistically not significant longer median OS (+4.7 months) in the OFA arm. As only few patients had the chance to receive a kinase inhibitor later, the study displays the survival of BFR CLL patients in the period prior to receiving small molecule inhibitors. This and other studies have demonstrated a longer PFS with the use of low-dose maintenance CD20 monoclonal antibody therapy vs not, a finding that may be re-explored in the new targeted therapeutic landscape in CLL. OFA is a safe option in multi-resistant advanced CLL cases.Discl...
Source: Blood - Category: Hematology Authors: Tags: 642. CLL: Therapy, excluding Transplantation Source Type: research
We described the case of an 82-year-old man diagnosed with recurrent MCC with cardiac and gastric metastasis who presented with poor oral intake and severe weight loss. The patient was diagnosed with MCC 3 years ago and treated with surgical resection and radiation. Interventions: We performed stomach biopsy in edematous lesion. And fluoroscopy and ultrasound guided biopsy of the cardiac mass was performed. Diagnoses: MCC with synchronous metastases to the heart and stomach. Outcomes: The primary lesion had complete resolution and the patient remained disease free on regular follow-up every 6 months for 2 and half...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Publication date: Available online 13 April 2018Source: Respiratory InvestigationAuthor(s): Kohei Otsubo, Isamu Okamoto, Naoki Hamada, Yoichi NakanishiAbstractInterstitial lung disease (ILD) is a risk factor for lung cancer development and is frequently observed in patients with lung cancer. Individuals with ILD have been excluded from most prospective clinical trials of lung cancer therapies because of the risk of ILD acute exacerbation. Thus, the optimal anticancer drug treatment for such patients has yet to be established. Tyrosine kinase inhibitors are avoided for the treatment of advanced non–small cell lung can...
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
Discussion of advocacy for the cause is a usual feature of our community, as we try things and attempt to make progress in persuading the world that rejuvenation research is plausible, practical, and necessary. There are more people engaged in advocacy now than at any time in the past decade, and so discussions of strategy come up often. New ventures kicked off in 2017 include the Geroscience online magazine, and among the existing ventures the LEAF / Lifespan.io volunteers seem to be hitting their stride. The mainstream media continues to be as much a hindrance as a help, and where it is a help you will usually find Aubre...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSION: Poor response against pneumococcal vaccines increases the susceptibility of respiratory diseases in these patients. In patients with NHL treated with RTX, the benefits achieved with IVIg replacement for the control of recurrent infectious diseases is of paramount importance. Clinicians dealing with monoclonal antibodies against cancer therapy, especially RTX, should be aware of the increasing risks for symptomatic induced hypogammaglobulinemia and respiratory infections. PMID: 29094629 [PubMed - as supplied by publisher]
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
Conclusions The incidence of post-bronchoscopy pneumonia in patients with lung cancer was not rare and associated with adverse effects on the clinical course. A simple 3-point predictive score identified patients with lung cancer at high risk of post-bronchoscopy pneumonia prior to the procedure.
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
Introduction: Interstitial lung diseases induced by anticancer agents (ILD-AA) are known to be a rare adverse effect of anti-cancer therapy. However, predictive prognostic fibrotic biomarkers of ILD-AA have not been identified in patients with advanced lung cancer (ALC).Aim: To analyze the association between serum fibrotic biomarkers, including KL-6 and surfactant protein D (SP-D), onset and types of ILD-AA by chest high resolution computed tomography (HRCT) findings in ALC patients.Methods: KL-6 and SP-D were defined as the difference between the values of KL-6 and SP-D level at the onset of ILD-AA and their respective v...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: 1.5 Diffuse Parenchymal Lung Disease Source Type: research
This study describes pulmonary outcomes among childhood cancer survivors and evaluates their impact on daily activities. METHODSThe incidence of pulmonary outcomes (asthma, chronic cough, emphysema, lung fibrosis, oxygen need, and recurrent pneumonia) reported among 5‐year cancer survivors (n = 14,316) and the incidence of death due to pulmonary causes among all eligible survivors (n = 20,690) in the Childhood Cancer Survivor Study were compared with those for sibling controls (n = 4027) with cumulative incidence, standardized mortality ratio (SMR), and piecewise exponential mode...
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Hospitals | Pneumonia